GET DAILY SIGNALSCLOV Builds Momentum as ALHC Navigates Medicare Advantage Challenges
Key Takeaways
- Diverging catalysts: CLOV recently received a Medicare Advantage (MA) Star Rating upgrade to five stars, while ALHC suffered a downgrade on its largest California contract.
- Profitability inflection: Clover Health has turned GAAP (Generally Accepted Accounting Principles) profitable, whereas Alignment Healthcare's earnings path faces renewed cost and rating overhangs.
- Momentum contrast: CLOV shares are up sharply year to date on strong membership growth, while ALHC trades near 52-week lows after a steep reset.
- Different models: Both serve Medicare members, but CLOV positions itself as a physician-enabling technology company, while ALHC is a tech-enabled Medicare Advantage insurer.
- Risk profiles differ: ALHC faces quality-rating and medical-cost uncertainty; CLOV faces valuation and profitability-consistency questions after a rapid rally.
The Diverging Paths of ALHC and CLOV
Alignment Healthcare and Clover Health both compete in Medicare Advantage, the private alternative to traditional Medicare. Their recent market moves, however, have pointed in opposite directions. This comparison matters for investors weighing two technology-focused names at different points in the sentiment cycle. One is working through a quality-rating issue while the other benefits from an upgrade and a move into profitability. The contrast offers a useful lens on momentum versus valuation in the sector.
ALHC's Recent Setback and Underlying Strength
ALHC, or Alignment Healthcare, Inc., runs a technology-enabled Medicare Advantage insurer aimed at seniors through its AVA platform for claims and clinical automation. Sentiment has shifted negative after the Centers for Medicare & Medicaid Services lowered the Star Rating on its largest California HMO contract from 4.0 to 3.5 stars. For plan year 2028, the share of members in 4-star-or-higher plans dropped from roughly 98% to about 24–25%. Analysts at BofA, JPMorgan, and William Blair responded by cutting ratings or targets, pushing the stock to a new 52-week low. I checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Fundamentals remain more positive. Alignment posted its first quarterly profit and grew membership about 31% year over year to roughly 284,800 members, with full-year revenue guidance near $5.2 billion. It has also added the Hoag health system to its California network. The ratings overhang and medical-cost questions have nevertheless dominated the near-term outlook.
CLOV's Upward Trajectory and Profit Milestone
CLOV, or Clover Health Investments, Corp., operates as a physician-enablement technology company centered on the Clover Assistant AI platform that helps physicians manage chronic conditions. It also runs a growing Medicare Advantage business and Counterpart Health subsidiary. Recent developments have been favorable: CMS raised Clover's flagship PPO plan to a perfect five-star rating and its HMO plan to 4.5 stars. I also reviewed this with Tickeron’s AI Trend Prediction Engine to confirm the pattern.
Financially, Clover posted GAAP net income of about $28 million in the latest quarter, reversing a year-ago loss, and expects its first full-year GAAP profit in 2026. Medicare Advantage membership rose roughly 48% year over year to about 157,000, and the company lifted full-year revenue and adjusted EBITDA guidance. Shares have risen substantially year to date, though the speed of the advance has added valuation and volatility considerations.
Head-to-Head Comparison
The companies differ in business models and near-term drivers. Alignment acts as a full-risk Medicare Advantage insurer that bears medical costs directly and relies on Star Ratings for bonus revenue and enrollment. Its technology edge lies in administrative automation. Clover leads with its Clover Assistant software and a high-choice PPO product, treating technology as the core differentiator while scaling membership.
CLOV currently holds the momentum edge thanks to the five-star rating, membership growth, and profitability milestone. ALHC confronts the reverse situation, with a ratings downgrade affecting more than 75% of its members. Risk factors also vary: ALHC is exposed to medical-cost trends and rating recovery, while CLOV must sustain thin margins and support a valuation that has expanded rapidly. Both remain subject to broader Medicare Advantage reimbursement and regulatory trends.
My Assessment of the Relative Positioning
Based on trend consistency, catalyst quality, and relative positioning, the balance currently tilts toward CLOV over ALHC. Clover Health's Star Rating improvement, membership expansion, and profitability shift create a clearer positive direction, whereas Alignment Healthcare deals with a ratings-driven reset and higher execution uncertainty. The view remains probabilistic: CLOV's quick appreciation and still-narrow margins bring their own volatility, and any stabilization in ALHC's ratings or costs could alter the picture. Relative momentum favors Clover Health for now, but conditions in this sector can shift quickly.
How Tickeron AI Trading Bots Support My Process
I often turn to Tickeron’s Trending AI Robots when comparing names like these. The curated selection highlights automated agents with strong recent performance across different strategies and timeframes, showing metrics such as annualized returns and win rates. Reviewing the list helps me identify which approaches align with current market conditions without needing to build models from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
CLOV sees MACD Histogram just turned negative
CLOV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 23, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 40 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLOV as a result. In 67 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLOV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 56 cases where CLOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
CLOV moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in 223 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CLOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLOV's P/B Ratio (6.621) is slightly higher than the industry average of (3.512). P/E Ratio (-117.250) is within average values for comparable stocks, (126.100). CLOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.970) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. CLOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare
Advertisement